Filing Flows › Teva Pharmaceutical Industries (TEVA) › Sale of goods revenue
Teva Pharmaceutical Industries (TEVA) Sale of goods revenue by quarter
Teva Pharmaceutical Industries' Sale of goods revenue was $3.7B in Q3 2026 (third quarter 2026), +4% from Q2 2026. Over the last 7 quarters it ranged from $3.4B (Q1 2026) to $3.9B (Q3 2025).
| Quarter | Sale of goods revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.7B | +4% | -4% |
| Q2 2026 | $3.6B | +6% | -0.9% |
| Q1 2026 | $3.4B | -8% | -0.2% |
| Q4 2025 | $3.7B | -6% | — |
| Q3 2025 | $3.9B | +7% | — |
| Q2 2025 | $3.6B | +7% | — |
| Q1 2025 | $3.4B | — | — |
Q3 2026 at a glance
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
Questions
What is Teva Pharmaceutical Industries' Sale of goods revenue?
Teva Pharmaceutical Industries' Sale of goods revenue was $3.7B in Q3 2026 (third quarter 2026), +4% from Q2 2026.
How has Teva Pharmaceutical Industries' Sale of goods revenue changed?
Over the last 7 quarters it ranged from $3.4B (Q1 2026) to $3.9B (Q3 2025).
Q3 2026 results → · How Teva Pharmaceutical Industries makes money →